The evolution and impact of therapy in multiple myeloma

被引：26

作者：

Laubach, Jacob P. ^{[1
]}

Richardson, Paul G. ^{[1
]}

Anderson, Kenneth C. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA

来源：

MEDICAL ONCOLOGY | 2010年 / 27卷

关键词：

Multiple myeloma; Stem cell transplantation; Lenalidomide; Thalidomide; Bortezomib; STEM-CELL TRANSPLANTATION; LENALIDOMIDE PLUS DEXAMETHASONE; BONE-MARROW-TRANSPLANTATION; COMBINATION CHEMOTHERAPY; MAINTENANCE THERAPY; IMPROVES SURVIVAL; ELDERLY-PATIENTS; CLINICAL-TRIAL; T-CELLS; THALIDOMIDE;

D O I：

10.1007/s12032-010-9442-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma is a clonal B-cell malignancy characterized by aberrant expression of plasma cells wtihin the bone marrow, and is associated with the well known clinical manifestations anemia, bone disease, renal dysfunction, hypercalcemia, and recurrent infections. For many years, melphalan and prednisone represented the standard of care in multiple myeloma therapy, with stem cell transplantation reserved for selected patients. Treatment of the disease has evolved rapidly over the past decade, however, with the development and utilization of thalidomide, lenalidomide, and bortezomib. As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy.

引用

页码：1 / 6

页数：6

共 84 条

[21]

Cavo M, 2008, BLOOD, V112, P586

[22] Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications [J].

Chang, David H. ;

Liu, Nancy ;

Klimek, Virginia ;

Hassoun, Hani ;

Mazumder, Amitabha ;

Nimer, Stephen D. ;

Jagannath, Sundar ;

Dhodapkar, Madhav V. .

BLOOD, 2006, 108 (02) :618-621

[23] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[24] SINGLE, SEQUENTIAL, AND MULTIPLE ALKYLATING AGENT THERAPY FOR MULTIPLE-MYELOMA - A CALGB STUDY [J].

COOPER, MR ;

MCINTYRE, OR ;

PROPERT, KJ ;

KOCHWA, S ;

ANDERSON, K ;

COLEMAN, M ;

KYLE, RA ;

PRAGER, D ;

RAFLA, S ;

ZIMMER, B .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1331-1339

[25] Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides [J].

Curti, Antonio ;

Tosi, Patrizia ;

Comoli, Patrizia ;

Terragna, Carolina ;

Ferri, Elisa ;

Cellini, Claudia ;

Massaia, Massimo ;

D'Addio, Alessandra ;

Giudice, Valeria ;

Di Bello, Cristiana ;

Cavo, Michele ;

Conte, Roberto ;

Gugliotta, Gabriele ;

Baccarani, Michele ;

Lemoli, Roberto M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) :415-424

[26] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[27] Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].

Davies, FE ;

Raje, N ;

Hideshima, T ;

Lentzsch, S ;

Young, G ;

Tai, YT ;

Lin, B ;

Podar, K ;

Gupta, D ;

Chauhan, D ;

Treon, SP ;

Richardson, PG ;

Schlossman, RL ;

Morgan, GJ ;

Muller, GW ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2001, 98 (01) :210-216

[28]

DIMOPOULOS MA, 1993, BLOOD, V82, P2324

[29] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Spencer, Andrew ;

Attal, Michael ;

Prince, H. Miles ;

Harousseau, Jean-Luc ;

Dmoszynska, Anna ;

San Miguel, Jesus ;

Hellmann, Andrzej ;

Facon, Thierry ;

Foa, Robin ;

Corso, Alessandro ;

Masliak, Zvenyslava ;

Olesnyckyj, Marta ;

Yu, Zhinuan ;

Patin, John ;

Zeldis, Jerome B. ;

Knight, Robert D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132

[30] Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro [J].

Dredge, K ;

Horsfall, R ;

Robinson, SP ;

Zhang, LH ;

Lu, L ;

Tang, Y ;

Shirley, MA ;

Muller, G ;

Schafer, P ;

Stirling, D ;

Dalgleish, AG ;

Bartlett, JB .

MICROVASCULAR RESEARCH, 2005, 69 (1-2) :56-63

← 1 2 3 4 5 6 7 8 9 →